CTOs on the Move

Womens International Pharmacy

www.womensinternational.com

 
It is the goal of Women's International Pharmacy, Inc. to provide excellent service and quality compounded prescriptions to our customers. At Women's International Pharmacy, Inc., we are dedicated to providing custom compounded doses of bioidentical
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Euro Pharma

Euro Pharma is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AQP - Affordable Quality Pharmaceuticals

AQP - Affordable Quality Pharmaceuticals, Inc. is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Actavis

Actavis is a unique global specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The Company has global headquarters in Dublin, Ireland. Actavis markets a broad portfolio of branded pharmaceuticals and is focused on developing new medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. Actavis is also the world`s third-largest generics prescription drug manufacturer, marketing generic, branded generic, and Over-the-Counter (OTC) products in more than 60 countries. Actavis Global Operations has more than 35 manufacturing and distribution facilities around the world and includes Anda, Inc., a U.S. pharmaceutical product distributor.

RxElite (Main)

RxElite (Main) is a Meridian, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.